Diabetic macular edema (DME) is a complication of diabetes, caused by fluid buildup and swelling in the retina that can damage vision. Without proper treatment, DME can severely impact visual clarity.
VABYSMO (faricimab-svoa) is approved to treat DME. It’s thought to block 2 causes of vision loss (VEGF and Ang-2),† proteins that drive abnormal blood vessel swelling, leakage, and growth. The benefit of blocking Ang-2 has yet to be established. It also improves vision quickly.* On average, people gained 6 letters at 1 month after their first treatment and gained and maintained 11 letters over 1 year on an eye chart with VABYSMO, similar to aflibercept 2 mg.
VABYSMO is given by injection into the eye. Initial dosing will be every 4 weeks, then dosing is determined by your doctor based on how you respond. You may be able to go up to 4 months between treatments.‡
The possible serious side effects of VABYSMO were inflammation and detached retina (separation of the retina from the back of the eye); a temporary increase in eye pressure; although not common, there is a risk of a stroke or heart attack; severe inflammation of vessels in the retina. These are not all the possible side effects of VABYSMO.